Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, ...
CARY, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group ...
Kamada and Chiesi Enter into a Strategic Agreement for the Distribution of Kamada's Inhaled AAT Drug for Treatment of Alpha-1 Antitrypsin Deficiency in Europe, Turkey and Former CIS Countries , Ltd.
Chiesi Group ("Chiesi"), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025.
WOODBURY, Minn.--(BUSINESS WIRE)--Kindeva Drug Delivery, a global leader in contract drug delivery development and manufacturing services and technology, and H&T Presspart (a division of the Heitkamp ...
Chiesi Group announces that it has successfully completed a Phase I trial of its inhaled PDE4 (phosphodiesterase 4) inhibitor, denoted CHF 6001, a new chemical entity developed for the treatment of ...
Forbes contributors publish independent expert analyses and insights. I write about businesses creating a more sustainable economic system. With a two-pronged focus on research and sustainability, a ...
Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results